FOLD Stock Forecast 2025-2026
Distance to FOLD Price Targets
FOLD Price Momentum
10 Quality Stocks Worth Considering Now
Researching Amicus (FOLD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on FOLD and similar high-potential opportunities.
Latest FOLD Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, FOLD has a bullish consensus with a median price target of $17.00 (ranging from $12.00 to $21.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $6.83, the median forecast implies a 148.9% upside. This outlook is supported by 9 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kristen Kluska at Cantor Fitzgerald, projecting a 207.5% upside. Conversely, the most conservative target is provided by Jeffrey Hung at Morgan Stanley, suggesting a 75.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FOLD Analyst Ratings
FOLD Price Target Range
Latest FOLD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FOLD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 20, 2025 | Needham | Gil Blum | Hold | Reiterates | $0.00 |
| Feb 20, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $17.00 |
| Jan 15, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $21.00 |
| Jan 13, 2025 | Needham | Gil Blum | Hold | Reiterates | $0.00 |
| Dec 13, 2024 | Morgan Stanley | Jeffrey Hung | Equal-Weight | Downgrade | $12.00 |
| Nov 12, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $17.00 |
| Nov 7, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $15.00 |
| Nov 7, 2024 | UBS | Buy | Maintains | $0.00 | |
| Nov 7, 2024 | Needham | Gil Blum | Hold | Reiterates | $0.00 |
| Nov 7, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $21.00 |
| Oct 17, 2024 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $15.00 |
| Oct 11, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $18.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $20.00 |
| Sep 6, 2024 | Jefferies | Dennis Ding | Buy | Initiates | $18.00 |
| Aug 16, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $16.00 |
| Aug 9, 2024 | Needham | Gil Blum | Hold | Reiterates | $0.00 |
| May 30, 2024 | Wells Fargo | Overweight | Initiates | $18.00 | |
| May 14, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Upgrade | $13.00 |
| May 10, 2024 | UBS | Karl Chalabala | Buy | Maintains | $19.00 |
| May 10, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $19.00 |
Amicus Therapeutics Inc. (FOLD) Competitors
The following stocks are similar to Amicus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amicus Therapeutics Inc. (FOLD) Financial Data
Amicus Therapeutics Inc. has a market capitalization of $2.10B with a P/E ratio of -37.9x. The company generates $528.30M in trailing twelve-month revenue with a -10.6% profit margin.
Revenue growth is +30.1% quarter-over-quarter, while maintaining an operating margin of +10.7% and return on equity of -31.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Amicus Therapeutics Inc. (FOLD) Business Model
About Amicus Therapeutics Inc.
Develops therapies for rare and orphan diseases.
The company focuses on creating drug candidates for rare genetic disorders using proprietary technology platforms. By addressing significant unmet medical needs, Amicus Therapeutics generates revenue through the development and commercialization of innovative treatments for conditions like Fabry disease and Pompe disease.
Founded in 2002, Amicus Therapeutics is positioned in the biotechnology sector and aims to transform healthcare markets by improving the standard of care for rare diseases. The company emphasizes patient-centric innovation and collaborates on cutting-edge research to drive advancements in treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
499
CEO
Mr. Bradley L. Campbell M.B.A.
Country
United States
IPO Year
2007
Website
amicusrx.comAmicus Therapeutics Inc. (FOLD) Latest News & Analysis
Investors are advised to buy healthcare stocks such as WGS, THC, RIGL, and ENSG for steady returns amid a shift in focus to the Trump administration's healthcare policies.
Shifting healthcare policies under the Trump administration may create opportunities for growth in specific healthcare stocks, indicating potential for steady returns amidst market changes.
Kaskela Law LLC is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) on behalf of long-term investors, as of April 7, 2025.
The investigation into Amicus Therapeutics may indicate potential legal or regulatory issues, impacting stock performance and investor confidence.
New drug approvals and positive pipeline developments support momentum in the Zacks Biomedical and Genetics industry, benefiting companies like GILD, BMRN, KRYS, ADMA, and FOLD.
New drug approvals and robust pipelines signal growth potential for GILD, BMRN, KRYS, ADMA, and FOLD, offering resilience in a volatile market, which could enhance investor confidence and returns.
New Strong Buy Stocks for April 1st
18 days agoAFRM, TKOMY, FOLD, MASS, and VFC were added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025.
Zacks Rank #1 indicates strong bullish sentiment, suggesting potential for significant stock appreciation in AFRM, TKOMY, FOLD, MASS, and VFC.
Amicus Therapeutics (FOLD) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for future stock trends.
Earnings reports can influence stock performance; upcoming developments may impact investor sentiment and stock price movements for Amicus Therapeutics.
Amicus Therapeutics, Inc. shows strong revenue growth from its rare disease therapies, targeting $1bn by 2028, with a solid financial position and market exclusivity until 2037.
Amicus Therapeutics' revenue growth and market potential, driven by successful therapies and minimal competition, indicate a promising investment opportunity despite recent stock decline.
Frequently Asked Questions About FOLD Stock
What is Amicus Therapeutics Inc.'s (FOLD) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Amicus Therapeutics Inc. (FOLD) has a median price target of $17.00. The highest price target is $21.00 and the lowest is $12.00.
Is FOLD stock a good investment in 2025?
According to current analyst ratings, FOLD has 9 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FOLD stock?
Wall Street analysts predict FOLD stock could reach $17.00 in the next 12 months. This represents a 148.9% increase from the current price of $6.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amicus Therapeutics Inc.'s business model?
The company focuses on creating drug candidates for rare genetic disorders using proprietary technology platforms. By addressing significant unmet medical needs, Amicus Therapeutics generates revenue through the development and commercialization of innovative treatments for conditions like Fabry disease and Pompe disease.
What is the highest forecasted price for FOLD Amicus Therapeutics Inc.?
The highest price target for FOLD is $21.00 from Kristen Kluska at Cantor Fitzgerald, which represents a 207.5% increase from the current price of $6.83.
What is the lowest forecasted price for FOLD Amicus Therapeutics Inc.?
The lowest price target for FOLD is $12.00 from Jeffrey Hung at Morgan Stanley, which represents a 75.7% increase from the current price of $6.83.
What is the overall FOLD consensus from analysts for Amicus Therapeutics Inc.?
The overall analyst consensus for FOLD is bullish. Out of 18 Wall Street analysts, 9 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are FOLD stock price projections?
Stock price projections, including those for Amicus Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.